Forteo

(Teriparatide)

Forteo

Drug updated on 11/15/2023

Dosage FormInjection (subcutaneous: 600 mcg/2.4 mL (250 mcg/mL))
Drug ClassParathyroid hormone analog
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy.
  • For increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy.
  • For treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Forteo (teriparatide) Prescribing Information.2021Lilly USA, LLC Indianapolis, IN

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines